ES2394952T3 - Derivados de axapéptido como inhibidores de la proteasa VIH - Google Patents

Derivados de axapéptido como inhibidores de la proteasa VIH Download PDF

Info

Publication number
ES2394952T3
ES2394952T3 ES11155667T ES11155667T ES2394952T3 ES 2394952 T3 ES2394952 T3 ES 2394952T3 ES 11155667 T ES11155667 T ES 11155667T ES 11155667 T ES11155667 T ES 11155667T ES 2394952 T3 ES2394952 T3 ES 2394952T3
Authority
ES
Spain
Prior art keywords
compound
pharmaceutically acceptable
composition
acceptable salt
efavirenz
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11155667T
Other languages
English (en)
Spanish (es)
Inventor
Roger D Tung
Scott L Harbeson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Concert Pharmaceuticals Inc
Original Assignee
Concert Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concert Pharmaceuticals Inc filed Critical Concert Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2394952T3 publication Critical patent/ES2394952T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576Six-membered rings
    • C07F9/58Pyridine rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
ES11155667T 2007-06-12 2008-06-12 Derivados de axapéptido como inhibidores de la proteasa VIH Active ES2394952T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US93420107P 2007-06-12 2007-06-12
US934201P 2007-06-12
US6762708P 2008-02-29 2008-02-29
US67627P 2008-02-29

Publications (1)

Publication Number Publication Date
ES2394952T3 true ES2394952T3 (es) 2013-02-07

Family

ID=39730784

Family Applications (3)

Application Number Title Priority Date Filing Date
ES11155667T Active ES2394952T3 (es) 2007-06-12 2008-06-12 Derivados de axapéptido como inhibidores de la proteasa VIH
ES09075359T Active ES2395137T3 (es) 2007-06-12 2008-06-12 Derivados de azapéptidos como inhibidores de la proteasa VIH
ES08252023T Active ES2356334T3 (es) 2007-06-12 2008-06-12 Derivados de azapéptidos como inhibidores de la proteasa vih.

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES09075359T Active ES2395137T3 (es) 2007-06-12 2008-06-12 Derivados de azapéptidos como inhibidores de la proteasa VIH
ES08252023T Active ES2356334T3 (es) 2007-06-12 2008-06-12 Derivados de azapéptidos como inhibidores de la proteasa vih.

Country Status (25)

Country Link
US (4) US20090036357A1 (en:Method)
EP (3) EP2003120B9 (en:Method)
JP (1) JP2010529196A (en:Method)
KR (2) KR20120029480A (en:Method)
CN (2) CN101711237B (en:Method)
AR (1) AR066972A1 (en:Method)
AT (2) ATE447554T1 (en:Method)
AU (1) AU2008267048C1 (en:Method)
BR (2) BRPI0823520A2 (en:Method)
CA (1) CA2692028C (en:Method)
CO (1) CO6241121A2 (en:Method)
CY (1) CY1109766T1 (en:Method)
DE (1) DE602008000255D1 (en:Method)
DK (1) DK2003120T3 (en:Method)
ES (3) ES2394952T3 (en:Method)
HR (1) HRP20100065T1 (en:Method)
MX (1) MX2009013565A (en:Method)
PL (1) PL2003120T3 (en:Method)
PT (1) PT2003120E (en:Method)
RS (1) RS51226B (en:Method)
RU (2) RU2448958C2 (en:Method)
SI (1) SI2003120T1 (en:Method)
TW (1) TW200908970A (en:Method)
WO (1) WO2008156632A1 (en:Method)
ZA (1) ZA200909079B (en:Method)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080241289A1 (en) * 2007-02-23 2008-10-02 Auspex Pharmaceuticals, Inc. Preparation and utility of non-nucleoside reverse transcriptase inhibitors
ES2394952T3 (es) 2007-06-12 2013-02-07 Concert Pharmaceuticals Inc. Derivados de axapéptido como inhibidores de la proteasa VIH
WO2010041241A2 (en) * 2008-10-06 2010-04-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Hiv-1 integrase derived peptides and compositions
WO2010132663A1 (en) * 2009-05-13 2010-11-18 Concert Pharmaceticals, Inc. Pegylated azapeptide derivatives as hiv protease inhibitors
WO2010135424A1 (en) * 2009-05-19 2010-11-25 Glaxosmithkline Llc Chemical compounds
CA2784530C (en) * 2009-12-21 2018-05-22 Janssen R&D Ireland Degradable removable implant for the sustained release of an active compound
WO2011080562A1 (en) 2009-12-29 2011-07-07 Hetero Research Foundation Novel aza-peptides containing 2,2-disubstituted cyclobutyl and/or substituted alkoxy benzyl derivatives as antivirals
PL3135656T3 (pl) 2011-06-20 2019-07-31 H. Lundbeck A/S Deuterowane 1-piperazyno-3-fenyloindany do leczenia schizofrenii
CN106543073A (zh) * 2015-09-17 2017-03-29 宁波杰尔盛化工有限公司 2-[4-(2-吡啶基)苄基]-肼羧酸叔丁酯的制备方法
AU2016361612B2 (en) * 2015-12-02 2021-07-29 Merck Sharp & Dohme Llc Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine
LT3436461T (lt) 2016-03-28 2024-03-12 Incyte Corporation Pirolotriazino junginiai kaip tam inhibitoriai
JOP20180009A1 (ar) 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
WO2019025250A1 (en) 2017-08-04 2019-02-07 Basf Se SUBSTITUTED TRIFLUOROMETHYLOXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI
CN111386273B (zh) 2017-09-27 2024-06-14 因赛特公司 可用作tam抑制剂的吡咯并三嗪衍生物的盐
CN113164398B (zh) * 2018-06-29 2023-11-03 因赛特公司 Axl/mer抑制剂的制剂
TWI829205B (zh) 2018-07-30 2024-01-11 美商基利科學股份有限公司 抗hiv化合物
WO2021178779A1 (en) 2020-03-06 2021-09-10 Incyte Corporation Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
AU2021257341A1 (en) * 2020-04-16 2022-11-17 The Medical College Of Wisconsin, Inc. Aerosolized formulations of HIV protease inhibitors for the treatment of airway reflux
CN114426568B (zh) * 2022-01-11 2023-04-25 嘉兴安谛康生物科技有限公司 2-氧代-3-吡咯烷基丙腈类化合物及其药物组合物和用途
CN121464144A (zh) 2023-05-31 2026-02-03 吉利德科学公司 抗hiv化合物
CN116987024B (zh) * 2023-08-01 2026-02-13 浙江荣耀生物科技股份有限公司 一种阿扎那韦中间体的制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI87783C (fi) 1985-05-15 1993-02-25 Wellcome Found Foerfarande foer framstaellning av terapeutiskt anvaendbara 2',3'-dideoxinukleosider
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5539122A (en) * 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
EP0674513B1 (en) 1992-12-29 1996-09-25 Abbott Laboratories Retroviral protease inhibiting compounds
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
ES2293638T3 (es) 1994-03-25 2008-03-16 Isotechnika, Inc. Mejora de la eficacia de farmacos por deuteracion.
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
TW409125B (en) * 1996-04-22 2000-10-21 Novartis Ag Antivirally active heterocyclic azahexane derivatives
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
WO1997046514A1 (en) 1996-05-31 1997-12-11 Novartis Ag Process for the preparation of hydrazine derivatives useful as intermediates for the preparation of peptide analogues
US6087383A (en) * 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
GB9914821D0 (en) 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
ATE234299T1 (de) * 1999-12-03 2003-03-15 Pfizer Prod Inc Sulfamoylheteroarylpyrazolverbindungen zur verwendung als analgetisches/entzündungshemmendes mittel
CA2444116C (en) 2001-05-03 2009-01-20 F. Hoffmann-La Roche Ag Pharmaceutical dosage form of amorphous nelfinavir mesylate
JP2005503425A (ja) 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション 所定の吸入ルートによる薬剤エステルの送出
IL159849A0 (en) 2001-08-31 2004-06-20 Bristol Myers Squibb Co Use of atazanavir in hiv therapy
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
US7553844B2 (en) 2003-02-21 2009-06-30 Jarrow Formulas, Inc. Methods for treatment of HIV or malaria using combinations of chloroquine and protease inhibitors
US20050131017A1 (en) 2003-12-11 2005-06-16 Degoey David A. HIV protease inhibiting compounds
US20050148523A1 (en) 2003-12-15 2005-07-07 Colonno Richard J. Method of treating HIV infection in atazanavir-resistant patients using a combination of atazanavir and another protease inhibitor
US7829720B2 (en) * 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
CA2571726C (en) * 2004-07-06 2013-05-21 Abbott Laboratories Prodrugs of hiv protease inhibitors
KR20070083839A (ko) 2004-09-29 2007-08-24 코디스 코포레이션 안정한 무정형 라파마이신 유사 화합물의 약학적 투약 형태
JP2008521934A (ja) 2004-12-03 2008-06-26 メルク エンド カムパニー インコーポレーテッド Ugt1a1によって代謝される薬物の薬物動態を改善するためのアタザナビルの使用
CA2624179A1 (en) * 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
JP2010502702A (ja) * 2006-09-05 2010-01-28 シェーリング コーポレイション 脂質管理およびアテローム性動脈硬化症および脂肪肝の治療治療において使用される医薬組成物
ES2394952T3 (es) 2007-06-12 2013-02-07 Concert Pharmaceuticals Inc. Derivados de axapéptido como inhibidores de la proteasa VIH
US20090076097A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched atazanavir
WO2010132663A1 (en) 2009-05-13 2010-11-18 Concert Pharmaceticals, Inc. Pegylated azapeptide derivatives as hiv protease inhibitors

Also Published As

Publication number Publication date
RU2448958C2 (ru) 2012-04-27
EP2116532B1 (en) 2011-12-07
ATE536343T1 (de) 2011-12-15
HK1136576A1 (en) 2010-07-02
DE602008000255D1 (de) 2009-12-17
CN102424668A (zh) 2012-04-25
AU2008267048A1 (en) 2008-12-24
CA2692028A1 (en) 2008-12-24
KR20100020033A (ko) 2010-02-19
WO2008156632A1 (en) 2008-12-24
RU2010100821A (ru) 2011-07-20
ZA200909079B (en) 2011-05-25
SI2003120T1 (sl) 2010-03-31
KR101185899B1 (ko) 2012-09-27
DK2003120T3 (da) 2010-03-15
RS51226B (sr) 2010-12-31
BRPI0813911A2 (pt) 2012-02-22
US20110009355A1 (en) 2011-01-13
RU2012101881A (ru) 2013-07-27
HK1127345A1 (en) 2009-09-25
PT2003120E (pt) 2010-02-11
AU2008267048C1 (en) 2013-01-17
US20090036357A1 (en) 2009-02-05
EP2003120B9 (en) 2010-06-02
EP2003120A1 (en) 2008-12-17
KR20120029480A (ko) 2012-03-26
CY1109766T1 (el) 2014-09-10
US8158805B2 (en) 2012-04-17
CN101711237B (zh) 2013-08-07
MX2009013565A (es) 2010-06-02
US20120165288A1 (en) 2012-06-28
EP2003120B1 (en) 2009-11-04
HRP20100065T1 (hr) 2010-03-31
CN101711237A (zh) 2010-05-19
PL2003120T3 (pl) 2010-04-30
TW200908970A (en) 2009-03-01
ES2395137T3 (es) 2013-02-08
ES2356334T3 (es) 2011-04-07
US8258309B2 (en) 2012-09-04
EP2322509A1 (en) 2011-05-18
EP2322509B1 (en) 2012-08-22
AR066972A1 (es) 2009-09-23
CO6241121A2 (es) 2011-01-20
AU2008267048B2 (en) 2012-05-31
US20130041156A1 (en) 2013-02-14
CA2692028C (en) 2013-06-04
JP2010529196A (ja) 2010-08-26
EP2116532A1 (en) 2009-11-11
ATE447554T1 (de) 2009-11-15
BRPI0823520A2 (pt) 2013-12-17

Similar Documents

Publication Publication Date Title
ES2394952T3 (es) Derivados de axapéptido como inhibidores de la proteasa VIH
ES2425183T3 (es) Derivados de oxazolidinonas sustituidas
US20090131363A1 (en) Deuterated darunavir
KR102132574B1 (ko) 트라이사이클릭 자이라제 억제제
WO2009148600A2 (en) Deuterated lysine-based compounds
ES2406479T3 (es) Derivado deuterado de 4-oxoquinolina para el tratamiento de la infección por VIH
US20130040914A1 (en) Prodrugs of an hiv reverse transcriptase inhibitor
EP2163553B1 (en) Arene connected polyamine macroring derivatives, preparation methods and pharmaceutical uses thereof
HK1154862A (en) Azapeptide derivatives as hiv protease inhibitors
HK1127345B (en) Azapeptide derivatives as hiv protease inhibitors
AU2012216511A1 (en) Azapeptide derivatives
HK1136576B (en) Azapeptide derivatives as hiv protease inhibitors
TW202214572A (zh) 經取代之芳基甲基脲、其類似物及晶形的合成及其使用方法
HK1138580B (en) Arene connected polyamine macroring derivatives, preparation methods and pharmaceutical uses thereof